New Medication for Type 2 Diabetes to be Commercialized in Tunisia

A new medication for the treatment of type 2 diabetes is set to be commercialized in Tunisia, with promising results in reducing blood sugar levels and weight loss. This was announced by Dr. Mehdi Kalthoum, a university professor and specialist in endocrinology at the Gafsa Regional Hospital, on Monday, May 4, 2026.

According to Dr. Kalthoum, this treatment stands out for its significant effectiveness in reducing blood sugar levels and glucose reserves in the body. It also contributes to weight loss, while being considered safe for health.

The commercialization of this medication is expected to take place in May in Tunisian pharmacies. However, Dr. Kalthoum emphasizes that its use requires a mandatory medical prescription from a doctor or specialist. He also assures that this treatment does not have any adverse effects on the heart or kidneys, even with prolonged use.

This medication represents a first in Tunisia in terms of therapeutic protocol, as it is administered in the form of a weekly injection containing four doses. To date, it is not covered by the National Health Insurance Fund. The estimated price of this medication is 355 dinars.

In a statement to Tunis Afrique Presse, Dr. Kalthoum highlighted that this new treatment could significantly improve the quality of life of patients and contribute to reducing complications related to diabetes. However, he also reminded that currently available treatments remain effective in controlling blood sugar levels in patients with type 2 diabetes.

In Tunisia, diabetes is a major public health issue. According to several studies, approximately 23% of the population suffers from it, with some estimates suggesting that one in five Tunisians is affected. Globally, the number of people affected exceeds 589 million, according to data from the International Diabetes Federation.